New York, USA – February 9, 2021 – DDA Platform, the major division of Creative Bioarray, focuses on developing cutting-edge products and high-quality services to promote research in drug discovery and development with the best strategies and protocols. Recently, Creative Bioarray announced the release of a wide range of in vitro models to evaluate drug permeability and predict drug absorption and distribution.
Membrane permeability is a key attribute to consider during drug design, especially when dealing with small molecules with intracellular targets because their efficacy is highly dependent on their ability to pass through the membrane. Meanwhile, permeability is an important factor affecting oral absorption, blood-brain barrier penetration, and drug transport to tissues and across cell membranes. The permeability of the drug across the membrane depends on the passive permeability and the sensitivity of the drug to the efflux or uptake of the drug transporter.
Creative Bioarray provides a wide range of complementary in vitro models to solve potential failures in the drug development process, such as poor permeability or interaction with efflux drug transporters. Based on the permeability model, Creative Bioarray can provide the following analysis services:
• Predict various osmotic processes (pericellular, transcellular)
• Estimate different intracellular concentrations (membrane, cytosolic, lysosome)
• Assess the impact of experimental variability on expected results
• Analysis of measured in vitro permeability data
Early prediction of drug metabolism and pharmacokinetic properties during drug discovery and development can help simplify the selection of lead compounds that are most likely to be useful drugs. The application of Caco-2 cell monolayer assay not only helps to determine intestinal permeability, but also can identify specific transporters or efflux proteins and intestinal phase II drug metabolizing enzymes. The Caco-2 permeability assays available on Creative Bioarray include passive permeability in Caco-2, MDR1 substrate, BCRP substrate and inhibitor evaluation.
The MDCK permeability assay is used to determine the permeability of the intestine or CNS and to study the outflow of drugs to find out whether the compound is suitable for oral administration or as a CNS therapeutic agent. The PAMPA model provided by Creative Bioarray provides a simplified permeability method by solving only a single transport mechanism. This avoids the complexity of active transport and metabolism, allowing compounds to rank on a single penetration factor.
“All absorption and permeability measurements can be used in standard human and animal model systems, and can be ordered separately combined order or as a key service option in our candidate evaluation package,” said Hannah Cole, the marketing director of Creative Biogene, she also added, “our professional team is capable to customize a solution for your needs and goals with low cost and high-quality solutions.”
About DDA Platform
As a mature division of Creative Bioarray, DDA Platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Country: United States